吸入氧化用于治疗COVID-19:一个开放式,并行,随机对照试验
Frederico Friedrich1,2, Marcelo Cypel3, Vinicius Schenk Michaelsen3
1Centro Infant, Department of Pediatrics, School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
ERJ open research
|August 28, 2025
概括
高度的吸入氧化 (iNO) 对住院COVID-19患者的安全改善了结果. 治疗增加了无补充氧气的时间,减少了住院时间.
科学领域:
- 肺部医学
- 危急护理医学
- 传染性疾病
背景情况:
- 高度的吸入氧化 (iNO) 显示出在上皮细胞中抑制SARS-CoV-2复制的潜力.
- 在住院的COVID-19患者中,iNO可以预防严重的疾病进展.
研究的目的:
- 在住院的COVID-19患者中评估吸入氧化 (iNO) 的安全性和有效性.
- 评估iNO对康复指标和临床结果的影响.
主要方法:
- 一项开放的随机临床试验涉及接受补充氧气的住院COVID-19患者.
- 患者被随机分配为接受标准治疗或标准治疗加iNO (160 ppm) 每天6小时.
- 主要安全终点是不良事件发生率;次要疗效终点是15天内没有补充氧气的日子.
主要成果:
- 在吸入iNO时没有报告任何不良反应.
- 与对照组的8天相比,iNO组的中位数是没有补充氧气的11天 (p=0. 044).
- 在iNO组中观察到显著的改善,包括更短的住院时间 (p=0. 004),改善的临床分数 (p<0. 05) 和更高的呼吸器支断奶率 (p=0. 005).
结论:
- 吸入氧化 (160 ppm) 治疗对于住院的COVID-19患者来说是耐受性良好且安全的.
- iNO治疗显著增加了没有补充氧气的日数,减少了住院时间,并改善了临床状态.
- 这些发现表明iNO是治疗住院COVID-19患者的有希望的辅助疗法.
相关概念视频
Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
317
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
317
COPD: Management Using Bronchodilators and Corticosteroids
305
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
305
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Administering Oxygen by Nasal Cannula
1.0K
Oxygen therapy is critical to patient care, especially for those struggling with respiratory issues. This intervention increases the oxygen concentration in the lungs, enhancing the amount of oxygen transported to the body's tissues. One standard method of delivering supplemental oxygen is through a nasal cannula, a non-invasive device that provides low to medium oxygen concentrations.
Nasal Cannulas
A nasal cannula is a lightweight tube split into two prongs placed in the nostrils,...
Nasal Cannulas
A nasal cannula is a lightweight tube split into two prongs placed in the nostrils,...
1.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251


